RIO DE JANEIRO, BRAZIL – A vaccine in nasal spray form against Covid-19 is being developed by researchers from the University of São Paulo (USP), in partnership with the Federal University of São Paulo (Unifesp) and the Oswaldo Cruz Foundation (Fiocruz).
In the study phase, the new immunization promises to be low cost, protect against variants and block the new virus still in the nose. It is expected to be available by the end of 2022.
“You already start to induce a response in the nasal epithelium and induce the production of an antibody that is very important . . .